RGNX
NASDAQREGENXBIO Inc.
Price$10.76+0.29 (+2.77%)
01:30 PM07:45 PM
News · 26 weeks57-47%
2026-02-152026-08-09
Mix3690d
- Insider14(39%)
- Other9(25%)
- SEC Filings8(22%)
- Offering3(8%)
- Earnings1(3%)
- Analyst1(3%)
Latest news
25 items- ANALYSTREGENXBIO downgraded by Barclays with a new price targetBarclays downgraded REGENXBIO from Overweight to Equal Weight and set a new price target of $12.00
- SECSEC Form 10-Q filed by REGENXBIO Inc.10-Q - REGENXBIO Inc. (0001590877) (Filer)
- SECREGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REGENXBIO Inc. (0001590877) (Filer)
- PRREGENXBIO Reports Second Quarter 2026 Financial Results and Operational HighlightsRGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalystTopline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ®**, expected in Q4 2026Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoingReaffirmed path forward for RGX-121 for Hunter syndrome with FDA during productive July Type A meeting; resubmission on track for Q3 2026Over $200 million new capital in July 2026 extends cash runway into Q4 2027Pro forma ending Q2 2026 cash, cash equivalents and marketabl
- INSIDERChief Medical Officer Pakola Steve covered exercise/tax liability with 7,468 shares, decreasing direct ownership by 4% to 205,541 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- INSIDERChief Strategy & Legal Officer Christmas Patrick J. covered exercise/tax liability with 4,699 shares, decreasing direct ownership by 2% to 205,968 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- PRREGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational HighlightsROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and operational highlights.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission t
- SECSEC Form 8-K filed by REGENXBIO Inc.8-K - REGENXBIO Inc. (0001590877) (Filer)
- PRREGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual MeetingOne-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroidsPrevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids Topline data from wet AMD pivotal studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026ROCKVILLE, Md.,, July 18, 2026 /PRNewswire/ -- R
- SECSEC Form 424B5 filed by REGENXBIO Inc.424B5 - REGENXBIO Inc. (0001590877) (Filer)
- PRREGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded WarrantsROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case before underwriting discounts and commissions. The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by REGENXBIO, are expected to be approximately $100.0 million. This offering is expected to close on July 20, 2026, subject to customary closing conditions. In addition, REGENXBIO has granted the underwriters a 30
- SECSEC Form FWP filed by REGENXBIO Inc.FWP - REGENXBIO Inc. (0001590877) (Subject)
- SECSEC Form 424B5 filed by REGENXBIO Inc.424B5 - REGENXBIO Inc. (0001590877) (Filer)
- PRREGENXBIO Announces Proposed Public Offering of Common StockROCKVILLE, Md., July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In addition, REGENXBIO intends to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of common shares sold in connection with the offering.Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-runni
- INSIDERChief Executive Officer Simpson Curran was granted 2,404 shares and covered exercise/tax liability with 6,818 shares, decreasing direct ownership by 1% to 338,053 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- INSIDERChief Medical Officer Pakola Steve exercised 2,161 shares at a strike of $7.86 and sold $29,476 worth of shares (2,161 units at $13.64) as part of a pre-agreed trading plan (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- SECAmendment: SEC Form SC TO-I/A filed by REGENXBIO Inc.SC TO-I/A - REGENXBIO Inc. (0001590877) (Subject)
- INSIDERChief Medical Officer Pakola Steve exercised 36,725 shares at a strike of $7.86 and sold $688,756 worth of shares (56,333 units at $12.23) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 213,009 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- SECAmendment: SEC Form SC TO-I/A filed by REGENXBIO Inc.SC TO-I/A - REGENXBIO Inc. (0001590877) (Subject)
- SECREGENXBIO Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - REGENXBIO Inc. (0001590877) (Filer)
- PRREGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million MilestoneNew long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026ROCKVILLE, Md., June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery. REGENXBIO will receive $100 million from AbbVie for this milestone."Dosing the first patient in the Phase IIb/III study is a significant milestone in our commitment with AbbVie to bring a one-time gene therapy to patients who continue to face progressive and vision-thr
- PRREGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator interestOn track to initiate BLA in Q3 2026 under the accelerated approval pathway supporting potential approval in 2H 2027ROCKVILLE, Md., June 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy. This milestone positions REGENXBIO to initiate a Biologics License Application (BLA) under the accelerated approval pathway in Q3 2026 for a potential approval by the U.S. Food and Drug Administration (FDA) in the second half of 2027.The BL
- PRREGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS IIFDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE® study will be reviewed on an expedited basis for approval via the accelerated approval pathway The Company expects to resubmit the BLA in Q3 2026 ROCKVILLE, Md., June 22, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced it has aligned with the U.S. Food and Drug Administration (FDA) regarding the next steps needed for a potential accelerated approval of NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121), the only potential one-time treatment and gene therapy for Mucopolysaccharidosis II (MPS II), an ultra-rare neurodegenerative disease also known as Hunter syndrome.Through a recent co
- SECAmendment: SEC Form SCHEDULE 13G/A filed by REGENXBIO Inc.SCHEDULE 13G/A - REGENXBIO Inc. (0001590877) (Subject)
- SECSEC Form SC TO-I filed by REGENXBIO Inc.SC TO-I - REGENXBIO Inc. (0001590877) (Subject)
RGNX FAQ
7 questionsWhat does REGENXBIO Inc. do?
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II...Where does RGNX stock trade?
REGENXBIO Inc. (RGNX) is listed on NASDAQ.What sector and industry is RGNX in?
REGENXBIO Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did REGENXBIO Inc. go public?
REGENXBIO Inc. (RGNX) completed its IPO in 2015.What are analysts saying about RGNX?
REGENXBIO Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $1200.00 price target on 2026-08-07. Recent price targets range from $1200.00 to $3800.00.What companies are similar to RGNX?
Notable peers in the same industry include QURE (uniQure N.V.), MGTX (MeiraGTx Holdings plc), RCKT (Rocket Pharmaceuticals Inc.), VYGR (Voyager Therapeutics Inc.). Compare RGNX side-by-side with any of them on Quantisnow.How can I track RGNX on Quantisnow?
Quantisnow aggregates REGENXBIO Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNX to receive live email and push alerts on every new disclosure.